Abstract
Drug-eluting coronary stents (DES) are widely used1 and entail sizeable Medicare hospital expenditures.2 However, the overall cost impact of DES has not been well quantified. Clear understanding of how new technologies like DES affect healthcare expenditures can provide insight into national trends in healthcare cost growth, of which new technology is presumably the leading driver.3 New technology may not only increase costs by being more expensive than previous treatments, but also by changing the patterns of care for chronic disease.4 Accordingly, we sought to assess the overall impact of DES on Medicare expenditures in a nationally-representative cohort of Medicare beneficiaries with coronary artery disease (CAD).
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
